| 前收市價 | 13.08 |
| 開市 | 13.40 |
| 買盤 | 12.68 x 300 |
| 賣出價 | 12.76 x 300 |
| 今日波幅 | 12.61 - 13.40 |
| 52 週波幅 | 4.22 - 18.12 |
| 成交量 | |
| 平均成交量 | 1,068,343 |
| 市值 | 777.389M |
| Beta 值 (5 年，每月) | 2.06 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -2.66 |
| 業績公佈日 | 2024年7月11日 - 2024年7月15日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 24.60 |
ZacksRoche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study
Roche's (RHHBY) Columvi, in combination with GemOx, achieves the primary endpoint of overall survival in a late-stage lymphoma study.
ZacksALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study
ALX Oncology (ALXO) announces positive results from an early to mid-stage study of an investigational combination regimen to treat indolent and aggressive R/R B-NHL.
ZacksNurix (NRIX) Up on Upbeat Initial Data From Phase I Cancer Study
Nurix (NRIX) rises on initial findings of clinical responses in the brain for its investigational targeted protein degrader, NX-5948, which is currently under development to treat B cell malignancies.
